Regulation of mammalian target of rapamycin and mitogen activated protein kinase pathways by BCR-ABL

Area of Science:

• Oncology
• Molecular Biology
• Signal Transduction

Background:

• BCR-ABL is a constitutively active tyrosine kinase implicated in leukemogenesis.
• Aberrant activation of mammalian target of rapamycin (mTOR) and mitogen-activated protein kinase (MAPK) signaling cascades is a hallmark of BCR-ABL-expressing leukemias.
• Deregulation of these pathways contributes to the development and progression of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).

Purpose of the Study:

• To review recent advances in understanding mTOR and MAPK signaling in BCR-ABL-driven leukemias.
• To discuss the therapeutic potential of targeting these pathways in CML and Ph+ ALL.

Main Methods:

• This is a review article, synthesizing existing research.
• Literature search and analysis of studies investigating BCR-ABL, mTOR, and MAPK signaling.
• Examination of preclinical and clinical data on targeted therapies.

Main Results:

• BCR-ABL signaling directly impacts mTOR and MAPK pathways, including ERK, JNK, and p38.
• Inhibition of mTOR or MAPK signaling demonstrates potential to overcome resistance and enhance antileukemic effects.
• Targeting these pathways is a viable strategy for treating CML and Ph+ ALL.

Conclusions:

• mTOR and MAPK pathways are critical mediators of BCR-ABL leukemogenesis.
• Selective inhibitors targeting mTOR and MAPK signaling represent a promising therapeutic avenue for CML and Ph+ ALL.
• Further research into combination therapies may enhance clinical outcomes.